# C_2013187EN.01000901.xml

| 29.6.2013 | EN | Official Journal of the European Union | C 187/9 |
| --- | --- | --- | --- |

29.6.2013

EN

Official Journal of the European Union

C 187/9

---

COMMISSION DECISION

of 28 June 2013

appointing members and alternates of the Committee for Advanced Therapies to represent clinicians and patients' associations

(Text with EEA relevance)

2013/C 187/08

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (1), and in particular Article 21(1) thereof,

1

Whereas:

| (1) | Regulation (EC) No 1394/2007 lays down specific rules concerning the authorisation, supervision and pharmacovigilance of advanced therapy medicinal products. Article 20 of that Regulation lays down that a Committee for Advanced Therapies shall be established within the European Medicines Agency. |
| --- | --- |

(1)

Regulation (EC) No 1394/2007 lays down specific rules concerning the authorisation, supervision and pharmacovigilance of advanced therapy medicinal products. Article 20 of that Regulation lays down that a Committee for Advanced Therapies shall be established within the European Medicines Agency.

| (2) | Subparagraph (c) of Article 21(1) of Regulation (EC) No 1394/2007 lays down that the Committee for Advanced Therapies shall include two members and two alternates appointed by the Commission, on the basis of a public call for expressions of interest and after consulting the European Parliament, in order to represent clinicians. |
| --- | --- |

(2)

Subparagraph (c) of Article 21(1) of Regulation (EC) No 1394/2007 lays down that the Committee for Advanced Therapies shall include two members and two alternates appointed by the Commission, on the basis of a public call for expressions of interest and after consulting the European Parliament, in order to represent clinicians.

| (3) | Subparagraph (d) of Article 21(1) of Regulation (EC) No 1394/2007 lays down that the Committee for Advanced Therapies shall include two members and two alternates appointed by the Commission, on the basis of a public call for expressions of interest and after consulting the European Parliament, in order to represent patients' associations. |
| --- | --- |

(3)

Subparagraph (d) of Article 21(1) of Regulation (EC) No 1394/2007 lays down that the Committee for Advanced Therapies shall include two members and two alternates appointed by the Commission, on the basis of a public call for expressions of interest and after consulting the European Parliament, in order to represent patients' associations.

| (4) | In accordance with Article 21(3) of Regulation (EC) No 1394/2007, the members and alternates of the Committee for Advanced Therapies are appointed for a period of 3 years. The term of office of the members and alternates appointed in 2009 has expired and therefore a new call has been undertaken in 2012. |
| --- | --- |

(4)

In accordance with Article 21(3) of Regulation (EC) No 1394/2007, the members and alternates of the Committee for Advanced Therapies are appointed for a period of 3 years. The term of office of the members and alternates appointed in 2009 has expired and therefore a new call has been undertaken in 2012.

| (5) | In accordance with Article 21(1) of Regulation (EC) No 1394/2007, a public call for expression of interest has been undertaken by the Commission. The European Parliament has been consulted on the results of the evaluation of the applications received, |
| --- | --- |

(5)

In accordance with Article 21(1) of Regulation (EC) No 1394/2007, a public call for expression of interest has been undertaken by the Commission. The European Parliament has been consulted on the results of the evaluation of the applications received,

HAS ADOPTED THIS DECISION:

Article 1

The following are hereby appointed members and alternates of the Committee for Advanced Therapies to represent clinicians for a term of 3 years, from 1 July 2013:

| — | Pieter DOEVENDANS (Member) and Esteve TRIAS (Alternate), |
| --- | --- |

—

Pieter DOEVENDANS (Member) and Esteve TRIAS (Alternate),

| — | Bernd GÄNSBACHER (Member) and Ramadan JASHARI (Alternate). |
| --- | --- |

—

Bernd GÄNSBACHER (Member) and Ramadan JASHARI (Alternate).

Article 2

The following are hereby appointed members and alternates of the Committee for Advanced Therapies to represent patients' associations for a term of 3 years, from 1 July 2013:

| — | Michele LIPUCCI DI PAOLA (Member) and Monica ENSINI (Alternate), |
| --- | --- |

—

Michele LIPUCCI DI PAOLA (Member) and Monica ENSINI (Alternate),

| — | Kieran BREEN (Member) and Mariette DRIESSENS (Alternate). |
| --- | --- |

—

Kieran BREEN (Member) and Mariette DRIESSENS (Alternate).

Done at Brussels, 28 June 2013.

For the Commission

Tonio BORG

Member of the Commission

---

(1)  OJ L 136, 30.4.2004, p. 1.

1

---